The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. You can access the conference call by dialing 800-579- 2543 within the U.S. or +1 785-424-1789 outside the U.S. a few minutes before 2:00 PM PT and referencing conference ID #9467851. ABOUT ENVISTA HOLDINGS CORPORATION FOR FURTHER INFORMATION Steph ...

BREA, Calif., June 3, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") and its charitable arm, the Envista Smile Project, announced today that it has partnered with the University of Southern California's (USC) Herman Ostrow School of Dentistry and committed a $2.1 million donation to USC's Dental Health Equity and Access to Care Initiative. The gift is part of both organizations' commitment to expand and improve access to oral health for those in need. FOR FURTHER INFORMATION Meli ...

Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide array of dentists' clinical need ...

Envista Holdings Corporation (NVST) reported adjusted earnings per share (EPS) of 26 cents in first-quarter 2024, down 31.6% year over year. The bottom line missed the Zacks Consensus Estimate by 16.1%.The adjustments include charges and benefits related to the amortization of acquired intangible assets, restructuring costs and asset impairment, among others.The company’s GAAP EPS was 14 cents in the quarter compared with the year-ago quarter’s figure of 25 cents.Revenues in DetailRevenues totaled $623.6 mi ...

Financial Data and Key Metrics Changes - In Q1 2024, the company reported sales of $623.6 million, representing a slight decrease compared to Q1 2023. Adjusted for currency exchange rates, core sales grew by 0.4% [21][22] - The adjusted EBITDA margin for the quarter was 14%, which is 420 basis points lower than in Q1 2023, primarily due to lower gross margins and significant investments in Spark and North American implants [22][36] - Adjusted diluted EPS was $0.26, down from $0.38 in the same period last year [22] Business Line Data and Key Metrics Changes - The orthodontic business saw over 15% growth, driven by strong performance in Spark Clear Aligners, with double-digit sequential growth in the number of active doctors [15][38] - The implant business experienced a modest decline, with strong growth in China offset by weaker demand in North America and Western Europe [16][23] - The Specialty Products and Technologies segment had a core revenue increase of 0.8%, with solid growth in Western Europe and emerging markets, but declines in North America [45] Market Data and Key Metrics Changes - Developed markets declined by 1.7%, with North America and Western Europe showing similar declines, while emerging markets grew by 10.2%, particularly strong in China [73] - Patient demand in North America remains resilient, but there is a shift towards basic hygiene and restorative treatments, with muted demand for higher-end specialty procedures [37][38] Company Strategy and Development Direction - The company aims to accelerate its orthodontic business and improve the commercial execution in North America, with a goal to achieve market growth by the end of 2024 [51][80] - Investments are being made to enhance the implant business, including adding over 60 sales and marketing resources and increasing training and education activities [75] - The company is focused on utilizing its diagnostics and digital capabilities to differentiate itself and win customers, with a commitment to continuous improvement and cost optimization [50][81] Management's Comments on Operating Environment and Future Outlook - The management remains cautiously optimistic about demand trends in 2024, believing that patients will prioritize dental care and clinicians will invest in digitizing their practices [15][36] - The leadership transition is seen as an opportunity to assess the current situation and build a viable plan for the remainder of the year [55] - The company is confident in its ability to create long-term value, supported by solid growth trends in the dental market [50][52] Other Important Information - The company generated free cash flow of $29.3 million in Q1, a significant improvement compared to the previous year, driven by better vendor management and lower CapEx [78] - The company is committed to reducing structural costs by an additional $30 million annually, with full impact expected in 2025 [81] Q&A Session Summary Question: Guidance for 2024 and second quarter - Management indicated that due to the leadership transition, guidance for 2024 would be assessed by the new CEO, but the focus remains on accelerating the orthodontic business and improving the North American implant business [55] Question: Level of spending on investments - Approximately $10 million was invested in Q1 across various areas, with about 70% expected to be ongoing costs and 30% being one-time expenses [57][90] Question: Market growth expectations for implants - The market growth for implants is expected to be around 3% to 5%, with the company aiming to close the gap in North America by the end of the year [94] Question: Pricing trends in the North American implant market - Management has not observed significant price erosion in the premium implant segment, despite challenges in the market [66][110] Question: Growth in China and VBP impact - Sales in China increased by over 50% in Q1, with expectations for continued growth despite the anticipated introduction of VBP for orthodontics in the second half of 2024 [119]

Envista (NVST) reported $623.6 million in revenue for the quarter ended March 2024, representing a year-over-year decline of 0.6%. EPS of $0.26 for the same period compares to $0.38 a year ago.The reported revenue represents a surprise of -0.87% over the Zacks Consensus Estimate of $629.06 million. With the consensus EPS estimate being $0.31, the EPS surprise was -16.13%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine the ...

Envista (NVST) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -16.13%. A quarter ago, it was expected that this maker of dental products would post earnings of $0.33 per share when it actually produced earnings of $0.29, delivering a surprise of -12.12%.Over the last four quarters, t ...

[Q1 2024 Results Overview](index=1&type=section&id=Q1%202024%20Results%20Overview) This section provides an overview of Envista Holdings Corporation's Q1 2024 financial performance, strategic focus, and leadership transition [Financial Highlights](index=1&type=section&id=Financial%20Highlights) Envista Holdings Corporation reported challenging first-quarter 2024 results, with reported sales of $623.6 million and core sales growth of 0.4%, while net income and adjusted net income decreased compared to the prior year Financial Highlights (in millions, except Core Sales Growth and Diluted EPS) | Metric | Q1 2024 (March 29, 2024) | Q1 2023 (March 31, 2023) | | :----------------------- | :----------------------- | :----------------------- | | Reported Sales | $623.6 million | $627.2 million | | Core Sales Growth | 0.4% | - | | Net Income | $23.6 million | $43.8 million | | Diluted EPS | $0.14 | $0.25 | | Adjusted Net Income | $45.8 million | $67.8 million | | Adjusted Diluted EPS | $0.26 | $0.38 | | Adjusted EBITDA | $87.2 million | $114.0 million | [CEO Commentary and Strategic Focus](index=1&type=section&id=CEO%20Commentary%20and%20Strategic%20Focus) The outgoing CEO acknowledged challenging Q1 results but highlighted progress in long-term investments and outlined strategic priorities for 2024 - Q1 results were challenging, but the company made meaningful progress in prioritizing long-term investments for growth and profitability[4](index=4&type=chunk) - The Spark business achieved **double-digit growth** and **expanded margins**[4](index=4&type=chunk) - The value implant business returned to growth, and the consumables business stabilized[4](index=4&type=chunk) - Key strategic focuses for 2024 include improving Spark margins, accelerating the North American implant business, and optimizing the operating structure using the Envista Business System[4](index=4&type=chunk) [Leadership Transition](index=1&type=section&id=Leadership%20Transition) Paul Keel has been appointed as Envista's new CEO, effective May 1, 2024, with outgoing CEO Amir Aghdaei transitioning to a Senior Advisor role - **Paul Keel** appointed as Envista's new Chief Executive Officer, effective May 1, 2024[4](index=4&type=chunk) - Amir Aghdaei, the outgoing CEO, will remain a shareholder and Senior Advisor to Envista[4](index=4&type=chunk) [Investor Conference Call Details](index=1&type=section&id=Investor%20Conference%20Call%20Details) Envista hosted an investor conference call on May 1, 2024, to discuss quarterly results, with materials available on its website - An investor conference call was held on **May 1, 2024**, at 2:00 P.M. PT[4](index=4&type=chunk) - Webcast, slide presentation, and replay are available on the 'Investors' section of Envista's website under 'Events & Presentations' and 'Quarterly Earnings'[4](index=4&type=chunk)[5](index=5&type=chunk) [About Envista](index=2&type=section&id=About%20Envista) Envista is a global dental products company with over 30 brands, offering a comprehensive portfolio across implants, orthodontics, and digital imaging, driven by the Envista Business System - Envista is a global family of over **30 trusted dental brands**, including Nobel Biocare, Ormco, DEXIS, and Kerr[6](index=6&type=chunk) - The company provides industry-leading dental consumables, solutions, technology, and services, covering dental implants, orthodontics, and digital imaging technologies[6](index=6&type=chunk) - Envista's operations are underpinned by the **Envista Business System (EBS)** methodology, an experienced leadership team, and a culture emphasizing continuous improvement, innovation, and customer focus[6](index=6&type=chunk) [Financial Statements](index=4&type=section&id=Financial%20Statements) This section presents Envista's condensed consolidated financial statements, including statements of operations, balance sheets, and cash flows for the reported periods [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For Q1 2024, Envista reported decreases in sales, gross profit, operating profit, and net income, primarily due to lower operating profit and higher SG&A expenses Condensed Consolidated Statements of Operations (in millions, except Diluted EPS) | Metric (in millions) | Three Months Ended March 29, 2024 | Three Months Ended March 31, 2023 | | :------------------- | :-------------------------------- | :-------------------------------- | | Sales | $623.6 | $627.2 | | Cost of sales | $267.3 | $264.5 | | Gross profit | $356.3 | $362.7 | | Operating expenses: | | | | SG&A | $284.9 | $266.1 | | R&D | $23.3 | $24.5 | | Operating profit | $48.1 | $72.1 | | Income before taxes | $35.3 | $55.7 | | Income tax expense | $11.7 | $11.9 | | Net Income | $23.6 | $43.8 | | Diluted EPS | $0.14 | $0.25 | [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 29, 2024, Envista's total assets slightly decreased, with an increase in cash and cash equivalents and a reduction in goodwill and intangible assets Condensed Consolidated Balance Sheets (in millions) | Metric (in millions) | As of March 29, 2024 | As of December 31, 2023 | | :----------------------------- | :------------------- | :---------------------- | | **ASSETS** | | | | Cash and cash equivalents | $948.5 | $940.0 | | Total current assets | $1,771.9 | $1,743.7 | | Goodwill | $3,259.8 | $3,292.2 | | Other intangible assets, net | $918.7 | $954.0 | | Total assets | $6,556.3 | $6,605.1 | | **LIABILITIES AND EQUITY** | | | | Total current liabilities | $781.3 | $780.8 | | Long-term debt | $1,390.5 | $1,398.1 | | Total stockholders' equity | $4,140.3 | $4,173.9 | | Total liabilities and equity | $6,556.3 | $6,605.1 | [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Envista significantly increased cash from operating activities in Q1 2024, leading to an overall increase in cash and cash equivalents by quarter-end Condensed Consolidated Statements of Cash Flows (in millions) | Metric (in millions) | Three Months Ended March 29, 2024 | Three Months Ended March 31, 2023 | | :--------------------------------------- | :-------------------------------- | :-------------------------------- | | Net cash provided by operating activities | $40.3 | $3.1 | | Net cash used in investing activities | $(10.7) | $(22.0) | | Net cash used in financing activities | $(2.6) | $(1.5) | | Net change in cash and cash equivalents | $8.5 | $(21.7) | | Ending balance of cash and cash equivalents | $948.5 | $585.2 | [Summary of Financial Metrics](index=7&type=section&id=Summary%20of%20Financial%20Metrics) This section provides a summary of Envista's key GAAP and non-GAAP financial metrics for the first quarter of 2024 and 2023 [GAAP Financial Metrics](index=7&type=section&id=GAAP%20Financial%20Metrics) Envista's Q1 2024 GAAP metrics show declines in profitability but a significant improvement in operating cash flow compared to the prior year GAAP Financial Metrics (in millions, except EPS) | GAAP Metric (in millions, except EPS) | Three Months Ended March 29, 2024 | Three Months Ended March 31, 2023 | | :------------------------------------ | :-------------------------------- | :-------------------------------- | | Gross Profit | $356.3 | $362.7 | | Operating Profit | $48.1 | $72.1 | | Net Income | $23.6 | $43.8 | | Diluted Earnings Per Share | $0.14 | $0.25 | | Operating Cash Flow | $40.3 | $3.1 | [Non-GAAP Financial Metrics](index=7&type=section&id=Non-GAAP%20Financial%20Metrics) Non-GAAP metrics for Q1 2024 indicate decreases in adjusted profitability measures, but free cash flow turned positive compared to Q1 2023 Non-GAAP Financial Metrics (in millions, except EPS) | Non-GAAP Metric (in millions, except EPS) | Three Months Ended March 29, 2024 | Three Months Ended March 31, 2023 | | :---------------------------------------- | :-------------------------------- | :-------------------------------- | | Adjusted Gross Profit | $358.0 | $364.2 | | Adjusted Operating Profit | $77.6 | $105.2 | | Adjusted Net Income | $45.8 | $67.8 | | Adjusted Diluted EPS | $0.26 | $0.38 | | Adjusted EBITDA | $87.2 | $114.0 | | Free Cash Flow | $29.3 | $(14.4) | [Segment Information](index=8&type=section&id=Segment%20Information) This section details Envista's sales, operating profit, and operating margins broken down by its Specialty Products & Technologies and Equipment & Consumables segments [Sales by Segment](index=8&type=section&id=Sales%20by%20Segment) Both Specialty Products & Technologies and Equipment & Consumables segments experienced slight sales declines in Q1 2024 compared to the prior year Sales by Segment (in millions) | Segment (in millions) | Three Months Ended March 29, 2024 | Three Months Ended March 31, 2023 | | :------------------------------ | :-------------------------------- | :-------------------------------- | | Specialty Products & Technologies | $408.7 | $410.0 | | Equipment & Consumables | $214.9 | $217.2 | | Total Sales | $623.6 | $627.2 | [Operating Profit by Segment](index=8&type=section&id=Operating%20Profit%20by%20Segment) Specialty Products & Technologies saw a significant decrease in operating profit, while Equipment & Consumables reported an increase in Q1 2024 Operating Profit by Segment (in millions) | Segment (in millions) | Three Months Ended March 29, 2024 | Three Months Ended March 31, 2023 | | :------------------------------ | :-------------------------------- | :-------------------------------- | | Specialty Products & Technologies | $44.2 | $71.1 | | Equipment & Consumables | $35.6 | $32.5 | | Other | $(31.7) | $(31.5) | | Total Operating Profit | $48.1 | $72.1 | [Operating Margins by Segment](index=8&type=section&id=Operating%20Margins%20by%20Segment) Specialty Products & Technologies' operating margin substantially decreased, while Equipment & Consumables improved its margin in Q1 2024 Operating Margins by Segment | Segment | Three Months Ended March 29, 2024 | Three Months Ended March 31, 2023 | | :------------------------------ | :-------------------------------- | :-------------------------------- | | Specialty Products & Technologies | 10.8 % | 17.3 % | | Equipment & Consumables | 16.6 % | 15.0 % | | Total | 7.7 % | 11.5 % | [Non-GAAP Measures and Reconciliations](index=2&type=section&id=Non-GAAP%20Measures%20and%20Reconciliations) This section explains Envista's non-GAAP financial measures and provides detailed reconciliations to their most directly comparable GAAP counterparts [Explanation of Non-GAAP Measures](index=2&type=section&id=Explanation%20of%20Non-GAAP%20Measures) Envista uses non-GAAP measures to provide additional insights into profitability trends, underlying growth, operational factors, and cash generation, supplementing GAAP results - All **'Adjusted' amounts**, including core sales growth and free cash flow, are non-GAAP items[7](index=7&type=chunk) - Non-GAAP measures provide useful information by offering additional ways to view results, helping investors understand long-term profitability, identify underlying growth trends, assess operational factors, and evaluate cash generation ability[30](index=30&type=chunk)[32](index=32&type=chunk) - The company does not reconcile forward-looking non-GAAP measures to GAAP due to inherent difficulties in predicting future impacts of currency translation, acquisitions, discontinued products, and other potential adjustments[7](index=7&type=chunk) [Adjusted Gross Profit and Margin Reconciliation](index=9&type=section&id=Adjusted%20Gross%20Profit%20and%20Margin%20Reconciliation) Adjusted Gross Profit for Q1 2024 was $358.0 million, slightly lower than Q1 2023, after adjusting for restructuring costs and asset impairments Adjusted Gross Profit and Margin Reconciliation (in millions) | Metric (in millions) | Three Months Ended March 29, 2024 | Three Months Ended March 31, 2023 | | :-------------------------------- | :-------------------------------- | :-------------------------------- | | Gross Profit | $356.3 | $362.7 | | Restructuring costs and asset impairments | $1.7 | $1.5 | | Adjusted Gross Profit | $358.0 | $364.2 | | Gross Margin | 57.1 % | 57.8 % | | Adjusted Gross Margin | 57.4 % | 58.1 % | [Adjusted Operating Profit Reconciliation](index=9&type=section&id=Adjusted%20Operating%20Profit%20Reconciliation) Consolidated Adjusted Operating Profit decreased in Q1 2024, with Specialty Products & Technologies seeing a notable decline, while Equipment & Consumables remained stable Adjusted Operating Profit Reconciliation (in millions) | Metric (in millions) | Three Months Ended March 29, 2024 | Three Months Ended March 31, 2023 | | :-------------------------------- | :-------------------------------- | :-------------------------------- | | **Consolidated** | | | | Operating Profit | $48.1 | $72.1 | | Amortization of intangibles | $22.6 | $27.9 | | Restructuring costs & impairments | $6.9 | $4.3 | | Acquisition related expenses | — | $0.9 | | Adjusted Operating Profit | $77.6 | $105.2 | | Adjusted Operating Profit as % of Sales | 12.4 % | 16.8 % | | **Specialty Products & Technologies** | | | | Operating Profit | $44.2 | $71.1 | | Adjusted Operating Profit | $61.9 | $88.4 | | Adjusted Operating Profit as % of Sales | 15.1 % | 21.6 % | | **Equipment & Consumables** | | | | Operating Profit | $35.6 | $32.5 | | Adjusted Operating Profit | $46.6 | $47.3 | | Adjusted Operating Profit as % of Sales | 21.7 % | 21.8 % | [Adjusted Net Income Reconciliation](index=10&type=section&id=Adjusted%20Net%20Income%20Reconciliation) Adjusted Net Income for Q1 2024 decreased to $45.8 million from $67.8 million in Q1 2023, after accounting for various adjustments and tax effects Adjusted Net Income Reconciliation (in millions) | Metric (in millions) | Three Months Ended March 29, 2024 | Three Months Ended March 31, 2023 | | :-------------------------------- | :-------------------------------- | :-------------------------------- | | Net Income | $23.6 | $43.8 | | Amortization of intangibles | $22.6 | $27.9 | | Restructuring costs & impairments | $6.9 | $4.3 | | Acquisition related expenses | — | $0.9 | | Tax effect of adjustments | $(7.6) | $(7.8) | | Discrete tax adjustments | $0.3 | $(1.3) | | Adjusted Net Income | $45.8 | $67.8 | [Adjusted Diluted Earnings Per Share Reconciliation](index=10&type=section&id=Adjusted%20Diluted%20Earnings%20Per%20Share%20Reconciliation) Adjusted Diluted EPS decreased to $0.26 in Q1 2024 from $0.38 in Q1 2023, reflecting the lower adjusted net income Adjusted Diluted Earnings Per Share Reconciliation | Metric | Three Months Ended March 29, 2024 | Three Months Ended March 31, 2023 | | :-------------------------------- | :-------------------------------- | :-------------------------------- | | Diluted Earnings | $0.14 | $0.25 | | Amortization of intangibles | $0.13 | $0.16 | | Restructuring costs & impairments | $0.04 | $0.02 | | Acquisition related expenses | — | $0.01 | | Tax effect of adjustments | $(0.05) | $(0.05) | | Discrete tax adjustments | — | $(0.01) | | Adjusted Diluted Earnings Per Share | $0.26 | $0.38 | [Adjusted EBITDA Reconciliation](index=10&type=section&id=Adjusted%20EBITDA%20Reconciliation) Adjusted EBITDA for Q1 2024 was $87.2 million, down from $114.0 million in Q1 2023, with a corresponding decline in its percentage of sales Adjusted EBITDA Reconciliation (in millions) | Metric (in millions) | Three Months Ended March 29, 2024 | Three Months Ended March 31, 2023 | | :-------------------------------- | :-------------------------------- | :-------------------------------- | | Net Income | $23.6 | $43.8 | | Interest expense, net | $12.9 | $16.7 | | Income tax expense | $11.7 | $11.9 | | Depreciation | $9.5 | $8.5 | | Amortization of intangibles | $22.6 | $27.9 | | Restructuring costs & impairments | $6.9 | $4.3 | | Acquisition related expenses | — | $0.9 | | Adjusted EBITDA | $87.2 | $114.0 | | Adjusted EBITDA as a % of Sales | 14.0 % | 18.2 % | [Core Sales Growth Reconciliation](index=11&type=section&id=Core%20Sales%20Growth%20Reconciliation) Consolidated core sales grew by 0.4% in Q1 2024, driven by positive currency exchange rates, with Specialty Products & Technologies showing growth Core Sales Growth Reconciliation | Segment | Total Sales Growth | Currency Exchange Rates Impact | Core Sales Growth | | :------------------------------ | :----------------- | :----------------------------- | :---------------- | | Consolidated | (0.6)% | 1.0 % | 0.4 % | | Specialty Products & Technologies | (0.3)% | 1.1 % | 0.8 % | | Equipment & Consumables | (1.1)% | 0.9 % | (0.2)% | - Core sales exclude sales from acquired businesses, discontinued products, and the impact of currency translation to identify underlying growth trends[25](index=25&type=chunk)[34](index=34&type=chunk) [Free Cash Flow Reconciliation](index=12&type=section&id=Free%20Cash%20Flow%20Reconciliation) Envista generated $29.3 million in Free Cash Flow in Q1 2024, a significant improvement from a negative free cash flow in the prior year Free Cash Flow Reconciliation (in millions) | Metric (in millions) | Three Months Ended March 29, 2024 | Three Months Ended March 31, 2023 | | :--------------------------------------- | :-------------------------------- | :-------------------------------- | | Net Operating Cash Provided by Operating Activities | $40.3 | $3.1 | | Less: payments for additions to PP&E | $(11.0) | $(17.5) | | Free Cash Flow | $29.3 | $(14.4) | - Free Cash Flow is used to understand the company's ability to generate cash without external financings, invest in its business, and pursue strategic opportunities[32](index=32&type=chunk) [Notes to Reconciliation of GAAP to Non-GAAP Financial Measures](index=13&type=section&id=Notes%20to%20Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Financial%20Measures) This section clarifies the rationale for excluding specific items from non-GAAP measures, focusing on costs inconsistent in frequency or size to provide a clearer view of ongoing performance - Restructuring costs are excluded because they are discrete plans, fundamentally different from ongoing productivity improvements, and not indicative of ordinary course operating costs[31](index=31&type=chunk)[34](index=34&type=chunk) - Amortization of acquisition-related and other intangible assets is excluded due to the unpredictable timing, size, and nature of acquisitions, which can obscure consistent comparisons of operating results[34](index=34&type=chunk) - Acquisition-related expenses, discrete tax adjustments, and the tax effect of adjustments are excluded as they occur with inconsistent frequency or are unrelated to commercial performance, potentially obscuring underlying business trends[31](index=31&type=chunk)[34](index=34&type=chunk) - Core sales exclude the effect of acquisitions, divested product lines, discontinued products, and currency translation to provide a more consistent view of underlying business trends[34](index=34&type=chunk) [Forward-Looking Statements and Disclaimers](index=2&type=section&id=Forward-Looking%20Statements%20and%20Disclaimers) This section contains a standard disclaimer regarding forward-looking statements, cautioning that actual results may differ materially due to various important factors and that the company does not undertake to update these statements - The press release contains forward-looking statements, and actual results, developments, and business decisions could differ materially from those suggested[8](index=8&type=chunk) - Key risk factors include global economic conditions, inflation, interest rates, international political and legal factors, market cyclicality, manufacturing and supply chain risks, IT security breaches, competition, regulatory compliance, and risks associated with acquisitions and intellectual property[8](index=8&type=chunk) - The company does not assume any obligation to update or revise any forward-looking statement, except as required by applicable law[8](index=8&type=chunk) [Contact Information](index=3&type=section&id=Contact%20Information) For investor inquiries, Stephen Keller, Principal Financial Officer of Envista Holdings Corporation, can be contacted at the provided address and telephone number - Contact for investor inquiries: **Stephen Keller**, Principal Financial Officer, Envista Holdings Corporation[9](index=9&type=chunk)

BREA, Calif., April 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) announced today the appointment of Paul Keel as Chief Executive Officer and a member of the Board of Directors effective May 1, 2024. He succeeds Amir Aghdaei, who will continue to support the transition as a senior advisor. "Paul's strong track record as CEO of a public, diversified, global innovation company makes him the right leader for Envista at this stage in our growth journey," said Scott Huennekens, chairman of E ...

BREA, Calif., April 11, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") announced today that the Envista Smile Project (Smile Project) donated $1.2 million in 2023 as part of the non-profit's commitment to expanding and improving access to oral health for those in need.  Donations in 2023, which include contributions from Envista employees, more than doubled over 2022. Since its founding in 2021, the Envista Smile Project has provided more than $2.2 million in value of goods and s ...